ImmuCell Corporation (ICCC) | Investment Case

1. Company Snapshot

1.a. Company Description

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.coli, coronavirus, and rotavirus.

The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets.In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.It sells its products through animal health distributors.

ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Show Full description

1.b. Last Insights on ICCC

The recent 3-month performance of ImmuCell Corporation was driven by strong sales growth, margin expansion, and increased demand for its flagship product, First Defense. The company reported record Q1 sales, with preliminary unaudited results indicating a significant increase in revenue. Additionally, ImmuCell announced the initiation of Investigational Product use of Re-Tain, a new product that is expected to contribute to the company's growth. The company's ability to expand its margins and return to earnings also suggests a positive trend.

1.c. Company Highlights

Last Price	7.54
Change Percentage	-0.79%
Open	7.52
Previous Close	7.6
Market Cap ( Millions)	68
Volume	19331
Year High	7.82
Year Low	4.52
M A 50	6.51
M A 200	6.24

FCF Yield	1.80%
Dividend Yield	0.00%
ROE	-3.59%
Debt / Equity	48.77%
Net Debt / EBIDTA	198.27%
Price To Book	2.52
Price Earnings Ratio	-65.59
Price To FCF	55.69
Price To sales	2.47
EV / EBITDA	16.39

2. ImmuCell Corporation Q4 2025 Earnings: A Resilient Turnaround

The valuation snapshot underscores the market’s cautious stance: a P/E of –67.24, a P/B of 2.58, and an EV/EBITDA of 16.75. These metrics reveal that, while the company has moved into profitability, its earnings remain volatile and its equity valuation is still heavily discounted relative to book value.

Publication Date: Apr -15

                                    📋 Highlights
                                    Net Profit Surge:
                                                Net operating profit reached $1.6M in 2025, a $3.3M improvement from 2024.
Gross Margin Expansion:
                                                Gross margin hit 41% in 2025, driven by manufacturing efficiencies and price hikes.
First Defense Growth:
                                                Domestic sales of First Defense grew 8.7% in Q4 2025 compared to Q4 2024.
Operating Profitability Turnaround:
                                                Operating income turned positive at $1.6M in 2025 after a $1.6M loss in 2024.
Strong Liquidity Position:
                                                Closed 2025 with $3.8M in cash and $13M in working capital.

                                

Manufacturing Capacity Expansion

In 2025, ImmuCell increased its manufacturing footprint to support growing demand, positioning itself to scale between 5 million and 6 million units annually. The expanded capacity has already alleviated the long‑standing backorder backlog and is expected to underpin the projected revenue growth for 2026 and 2027.

First Defense Franchise Growth

The First Defense line, aimed at preventing calf scours, delivered a 8.7% domestic sales lift in Q4 2025 compared to Q4 2024. This growth, coupled with the franchise’s focus on disease prevention, signals a strong market reception and a promising revenue stream moving forward.

Sales Force Enhancement

ImmuCell is bolstering its commercial reach by hiring a senior international market development leader and a new U.S. sales manager. These moves are designed to accelerate market penetration and sustain the momentum generated by the First Defense product.

Customer Loyalty Amid Supply Constraints

Despite recent price hikes and supply bottlenecks, customer loyalty has remained robust, with sales teams reporting high satisfaction and repeat orders. However, the backorder situation complicates churn metrics, as customers may seek alternative distributors during shortages.

Financial Position & Working Capital

The company closed 2025 with $3.8 million in cash and $13 million in working capital, while its net debt/EBITDA ratio stands at 1.98. These figures suggest a solid liquidity base that can support ongoing investments and operational needs.

Strategic Focus & Future Outlook

3. NewsRoom

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

Apr -13

Source: globenewswire.com

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

Apr -08

Source: globenewswire.com

ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – Here’s Why

Mar -26

Source: defenseworld.net

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

Mar -18

Source: globenewswire.com

ImmuCell Q4 Earnings Call Highlights

Mar -07

Source: defenseworld.net

ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve

Mar -06

Source:

ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript

Mar -05

Source: seekingalpha.com

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

Mar -04

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.40%)

6. Segments

Scours

Expected Growth: 7.4%

Growing demand for animal health products, increasing awareness about neonatal calf diarrhea, and rising adoption of vaccines in livestock industry drive the market growth.

Mastitis

Expected Growth: 7.4%

Growing demand for dairy products, increasing awareness of cow health, and rising adoption of mastitis prevention products drive the market growth, with ImmuCell's First Defense playing a key role in promoting cow health and milk production.

7. Detailed Products

First Defense

A natural, non-antibiotic product that helps to support a healthy immune system in newborn calves, reducing the risk of scours and other diseases.

Tri-Shield

A vaccine that helps to protect against three major diseases in cattle: BVD, IBR, and PI3.

Calf-Guard

A vaccine that helps to protect against scours and other diseases in calves.

Mast Out

A natural, non-antibiotic product that helps to reduce the incidence of mastitis in dairy cows.

8. ImmuCell Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

ImmuCell Corporation's products are moderately susceptible to substitutes, as there are alternative products available in the market, but they are not perfect substitutes.

Bargaining Power Of Customers

ImmuCell Corporation's customers have limited bargaining power due to the company's strong brand reputation and limited availability of alternative products.

Bargaining Power Of Suppliers

ImmuCell Corporation's suppliers have moderate bargaining power due to the availability of alternative suppliers, but the company's large scale of operations gives it some negotiating power.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the biotechnology industry, including high research and development costs and stringent regulatory requirements.

Intensity Of Rivalry

The intensity of rivalry in the biotechnology industry is high due to the presence of several established players and the need for continuous innovation to stay competitive.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	33.54%
Debt Cost	3.95%
Equity Weight	66.46%
Equity Cost	7.00%
WACC	5.97%
Leverage	50.47%

11. Quality Control: ImmuCell Corporation passed 4 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

ImmuCell

A-Score: 4.0/10

Value: 5.1

Growth: 3.0

Quality: 3.6

Yield: 0.0

Momentum: 9.0

Volatility: 3.3

1-Year Total Return ->

Zevra Therapeutics

A-Score: 3.9/10

Value: 4.6

Growth: 4.0

Quality: 6.0

Yield: 0.0

Momentum: 6.5

Volatility: 2.3

1-Year Total Return ->

Cidara Therapeutics

A-Score: 3.9/10

Value: 6.0

Growth: 3.2

Quality: 4.1

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

Arcturus Therapeutics

A-Score: 3.4/10

Value: 8.8

Growth: 6.2

Quality: 3.4

Yield: 0.0

Momentum: 1.0

Volatility: 1.0

1-Year Total Return ->

Verrica Pharmaceuticals

A-Score: 3.3/10

Value: 8.8

Growth: 3.7

Quality: 6.1

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

Orgenesis

A-Score: 3.3/10

Value: 6.2

Growth: 4.1

Quality: 5.9

Yield: 0.0

Momentum: 3.5

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

12.34%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

5.97%

ImmuCell Corporation - US4525253062

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ICCC

1.c. Company Highlights

Lower Growth

Medium Volatility

Fairly Valued

Revenues Beats

Stable Momentum

Weak Momentum

Cheaper

Average Quality

Lower Quality

Average Growth

Strong Momentum

Better Quality

Earnings Miss

2. ImmuCell Corporation Q4 2025 Earnings: A Resilient Turnaround

Manufacturing Capacity Expansion

First Defense Franchise Growth

Sales Force Enhancement

Customer Loyalty Amid Supply Constraints

Financial Position & Working Capital

Strategic Focus & Future Outlook

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.40%)

6. Segments

Scours

Expected Growth: 7.4%

Mastitis

Expected Growth: 7.4%

7. Detailed Products

First Defense

Tri-Shield

Calf-Guard

Mast Out

8. ImmuCell Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: ImmuCell Corporation passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

7.54$

Current Price

7.54$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA